Profiles

Keywords
Last Name
Institution

Matthew Meriggioli

TitleProfessor
InstitutionRush University, Rush Medical College
DepartmentNeurological Sciences
Address
vCardDownload vCard

    Collapse Overview 
    Collapse overview
    My Scopus ID is 6603932829.
    My NIH COMMONS name is MERIGGIOLIM.


    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Mendell JR, Al-Zaidy SA, Lehman KJ, McColly M, Lowes LP, Alfano LN, Reash NF, Iammarino MA, Church KR, Kleyn A, Meriggioli MN, Shell R. Five-Year Extension Results of the Phase 1 START Trial of Onasemnogene Abeparvovec in Spinal Muscular Atrophy. JAMA Neurol. 2021 07 01; 78(7):834-841. PMID: 33999158.
      View in: PubMed
    2. Mohassel P, Landon-Cardinal O, Foley AR, Donkervoort S, Pak KS, Wahl C, Shebert RT, Harper A, Fequiere P, Meriggioli M, Toro C, Drachman D, Allenbach Y, Benveniste O, B?hin A, Eymard B, Laf?ret P, Stojkovic T, Mammen AL, B?nnemann CG. Anti-HMGCR myopathy may resemble limb-girdle muscular dystrophy. Neurol Neuroimmunol Neuroinflamm. 2019 01; 6(1):e523. PMID: 30588482.
      View in: PubMed
    3. Grunseich C, Miller R, Swan T, Glass DJ, El Mouelhi M, Fornaro M, Petricoul O, Vostiar I, Roubenoff R, Meriggioli MN, Kokkinis A, Guber RD, Budron MS, Vissing J, Soraru G, Mozaffar T, Ludolph A, Kissel JT, Fischbeck KH. Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial. Lancet Neurol. 2018 12; 17(12):1043-1052. PMID: 30337273.
      View in: PubMed
    4. Cooper DS, Meriggioli MN, Bonomi PD, Malik R. Severe Exacerbation of Myasthenia Gravis Associated with Checkpoint Inhibitor Immunotherapy. J Neuromuscul Dis. 2017; 4(2):169-173. PMID: 28505981.
      View in: PubMed
    5. Meriggioli MN, Kordower JH. TDP-43 Proteinopathy: Aggregation and Propagation in the Pathogenesis of Amyotrophic Lateral Sclerosis. Mov Disord. 2016 08; 31(8):1139. PMID: 27214572.
      View in: PubMed
    6. Guptill JT, Soni M, Meriggioli MN. Current Treatment, Emerging Translational Therapies, and New Therapeutic Targets for Autoimmune Myasthenia Gravis. Neurotherapeutics. 2016 Jan; 13(1):118-31. PMID: 26510558.
      View in: PubMed
    7. Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM, Hehir MK, Hobson-Webb LD, Howard JF, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI. Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine. Muscle Nerve. 2016 Feb; 53(2):165-8. PMID: 26662952.
      View in: PubMed
    8. Meriggioli MN. The Clinical Spectrum of Necrotizing Autoimmune Myopathy: A Mixed Bag With Blurred Lines. JAMA Neurol. 2015 Sep; 72(9):977-9. PMID: 26192089.
      View in: PubMed
    9. Meriggioli MN, Roubenoff R. Prospect for pharmacological therapies to treat skeletal muscle dysfunction. Calcif Tissue Int. 2015 Mar; 96(3):234-42. PMID: 25363509.
      View in: PubMed
    10. Thiruppathi M, Sheng JR, Li L, Prabhakar BS, Meriggioli MN. Recombinant IgG2a Fc (M045) multimers effectively suppress experimental autoimmune myasthenia gravis. J Autoimmun. 2014 Aug; 52:64-73. PMID: 24388113.
      View in: PubMed
    11. Wolfe GI, Meriggioli MN, Ciafaloni E, Ruff RL. Introduction for myasthenia gravis and related disorders. Ann N Y Acad Sci. 2012 Dec; 1274:vii-viii. PMID: 23252910.
      View in: PubMed
    12. Thiruppathi M, Rowin J, Li Jiang Q, Sheng JR, Prabhakar BS, Meriggioli MN. Functional defect in regulatory T cells in myasthenia gravis. Ann N Y Acad Sci. 2012 Dec; 1274:68-76. PMID: 23252899.
      View in: PubMed
    13. Wolfe GI, Meriggioli MN, Ciafaloni E, Ruff RL. Introduction for Myasthenia Gravis and Related Disorders. Ann N Y Acad Sci. 2012 Dec; 1275:vii-viii. PMID: 23278589.
      View in: PubMed
    14. Thiruppathi M, Rowin J, Ganesh B, Sheng JR, Prabhakar BS, Meriggioli MN. Impaired regulatory function in circulating CD4(+)CD25(high)CD127(low/-) T cells in patients with myasthenia gravis. Clin Immunol. 2012 Dec; 145(3):209-23. PMID: 23110942.
      View in: PubMed
    15. Rowin J, Thiruppathi M, Arhebamen E, Sheng J, Prabhakar BS, Meriggioli MN. Granulocyte macrophage colony-stimulating factor treatment of a patient in myasthenic crisis: effects on regulatory T cells. Muscle Nerve. 2012 Sep; 46(3):449-53. PMID: 22907239.
      View in: PubMed
    16. Meriggioli MN, Sanders DB. Muscle autoantibodies in myasthenia gravis: beyond diagnosis? Expert Rev Clin Immunol. 2012 Jul; 8(5):427-38. PMID: 22882218.
      View in: PubMed
    17. Benatar M, Sanders DB, Burns TM, Cutter GR, Guptill JT, Baggi F, Kaminski HJ, Mantegazza R, Meriggioli MN, Quan J, Wolfe GI. Recommendations for myasthenia gravis clinical trials. Muscle Nerve. 2012 Jun; 45(6):909-17. PMID: 22581550.
      View in: PubMed
    18. Sheng JR, Muthusamy T, Prabhakar BS, Meriggioli MN. GM-CSF-induced regulatory T cells selectively inhibit anti-acetylcholine receptor-specific immune responses in experimental myasthenia gravis. J Neuroimmunol. 2011 Dec 15; 240-241:65-73. PMID: 22099723.
      View in: PubMed
    19. Brown CA, Scharner J, Felice K, Meriggioli MN, Tarnopolsky M, Bower M, Zammit PS, Mendell JR, Ellis JA. Novel and recurrent EMD mutations in patients with Emery-Dreifuss muscular dystrophy, identify exon 2 as a mutation hot spot. J Hum Genet. 2011 Aug; 56(8):589-94. PMID: 21697856.
      View in: PubMed
    20. Scharner J, Brown CA, Bower M, Iannaccone ST, Khatri IA, Escolar D, Gordon E, Felice K, Crowe CA, Grosmann C, Meriggioli MN, Asamoah A, Gordon O, Gnocchi VF, Ellis JA, Mendell JR, Zammit PS. Novel LMNA mutations in patients with Emery-Dreifuss muscular dystrophy and functional characterization of four LMNA mutations. Hum Mutat. 2011 Feb; 32(2):152-67. PMID: 20848652.
      View in: PubMed
    21. Sheng JR, Grimme S, Bhattacharya P, Stowell MH, Artinger M, Prabahakar BS, Meriggioli MN. In vivo adsorption of autoantibodies in myasthenia gravis using Nanodisc-incorporated acetylcholine receptor. Exp Neurol. 2010 Oct; 225(2):320-7. PMID: 20637753.
      View in: PubMed
    22. Podberezin M, Meriggioli MN, Locante A, Voros A, Valyi-Nagy T, Kajdacsy-Balla A. Hashimoto encephalopathy with fulminant myocarditis. Pathol Res Pract. 2010 Oct 15; 206(10):720-2. PMID: 20494527.
      View in: PubMed
    23. Bhattacharya P, Grimme S, Ganesh B, Gopisetty A, Sheng JR, Martinez O, Jayarama S, Artinger M, Meriggioli M, Prabhakar BS. Nanodisc-incorporated hemagglutinin provides protective immunity against influenza virus infection. J Virol. 2010 Jan; 84(1):361-71. PMID: 19828606.
      View in: PubMed
    24. Sheng JR, Li LC, Prabhakar BS, Meriggioli MN. Acetylcholine receptor-alpha subunit expression in myasthenia gravis: a role for the autoantigen in pathogenesis? Muscle Nerve. 2009 Aug; 40(2):279-86. PMID: 19609914.
      View in: PubMed
    25. Meriggioli MN, Sanders DB. Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009 May; 8(5):475-90. PMID: 19375665.
      View in: PubMed
    26. Meriggioli MN. Myasthenia gravis with anti-acetylcholine receptor antibodies. Front Neurol Neurosci. 2009; 26:94-108. PMID: 19349707.
      View in: PubMed
    27. Li LC, Sheng JR, Mulherkar N, Prabhakar BS, Meriggioli MN. Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Cancer Res. 2008 Sep 15; 68(18):7352-61. PMID: 18794122.
      View in: PubMed
    28. Sheng JR, Li LC, Ganesh BB, Prabhakar BS, Meriggioli MN. Regulatory T cells induced by GM-CSF suppress ongoing experimental myasthenia gravis. Clin Immunol. 2008 Aug; 128(2):172-80. PMID: 18502693.
      View in: PubMed
    29. Meriggioli MN, Sheng JR, Li L, Prabhakar BS. Strategies for treating autoimmunity: novel insights from experimental myasthenia gravis. Ann N Y Acad Sci. 2008; 1132:276-82. PMID: 18567878.
      View in: PubMed
    30. Meriggioli MN. IVIG in myasthenia gravis: getting enough "bang for the buck". Neurology. 2007 Mar 13; 68(11):803-4. PMID: 17353466.
      View in: PubMed
    31. Rowin J, Cheng G, Lewis SL, Meriggioli MN. Late appearance of dropped head syndrome after radiotherapy for Hodgkin's disease. Muscle Nerve. 2006 Nov; 34(5):666-9. PMID: 16897763.
      View in: PubMed
    32. Sheng JR, Li L, Ganesh BB, Vasu C, Prabhakar BS, Meriggioli MN. Suppression of experimental autoimmune myasthenia gravis by granulocyte-macrophage colony-stimulating factor is associated with an expansion of FoxP3+ regulatory T cells. J Immunol. 2006 Oct 15; 177(8):5296-306. PMID: 17015715.
      View in: PubMed
    33. Rowin J, Amato AA, Deisher N, Cursio J, Meriggioli MN. Mycophenolate mofetil in dermatomyositis: is it safe? Neurology. 2006 Apr 25; 66(8):1245-7. PMID: 16636243.
      View in: PubMed
    34. T?z?n E, Saini SS, Ghosh S, Rowin J, Meriggioli MN, Christadoss P. Predictive value of serum anti-C1q antibody levels in experimental autoimmune myasthenia gravis. Neuromuscul Disord. 2006 Feb; 16(2):137-43. PMID: 16427283.
      View in: PubMed
    35. Meriggioli MN. Use of immunoassays in neurological diagnosis and research. Neurol Res. 2005 Oct; 27(7):734-40. PMID: 16197810.
      View in: PubMed
    36. Meriggioli MN, Sanders DB. Advances in the diagnosis of neuromuscular junction disorders. Am J Phys Med Rehabil. 2005 Aug; 84(8):627-38. PMID: 16034233.
      View in: PubMed
    37. T?z?n E, Meriggioli MN, Rowin J, Yang H, Christadoss P. Myasthenia gravis patients with low plasma IL-6 and IFN-gamma benefit from etanercept treatment. J Autoimmun. 2005 May; 24(3):261-8. PMID: 15848049.
      View in: PubMed
    38. Rowin J, Meriggioli MN, T?z?n E, Leurgans S, Christadoss P. Etanercept treatment in corticosteroid-dependent myasthenia gravis. Neurology. 2004 Dec 28; 63(12):2390-2. PMID: 15623708.
      View in: PubMed
    39. Grazi G, Meriggioli M, Donati G. [Can the treatment with L-carnitine improve the inflammation in chronic hemodialysis patients?]. G Ital Nefrol. 2004 Nov-Dec; 21 Suppl 30:S204-7. PMID: 15750986.
      View in: PubMed
    40. Meriggioli MN, Sanders DB. Myasthenia gravis: diagnosis. Semin Neurol. 2004 Mar; 24(1):31-9. PMID: 15229790.
      View in: PubMed
    41. Meriggioli MN, Ciafaloni E, Al-Hayk KA, Rowin J, Tucker-Lipscomb B, Massey JM, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology. 2003 Nov 25; 61(10):1438-40. PMID: 14638974.
      View in: PubMed
    42. Meriggioli MN, Rowin J. Single fiber EMG as an outcome measure in myasthenia gravis: results from a double-blind, placebo-controlled trial. J Clin Neurophysiol. 2003 Sep-Oct; 20(5):382-5. PMID: 14702000.
      View in: PubMed
    43. Meriggioli MN, Rowin J, Richman JG, Leurgans S. Mycophenolate mofetil for myasthenia gravis: a double-blind, placebo-controlled pilot study. Ann N Y Acad Sci. 2003 Sep; 998:494-9. PMID: 14592919.
      View in: PubMed
    44. Meriggioli MN, Rowin J. Fatigue and abnormal neuromuscular transmission in Kennedy's disease. Muscle Nerve. 2003 Feb; 27(2):249-51. PMID: 12548535.
      View in: PubMed
    45. Gordon AJ, Meriggioli MN. Clinical immunopharmacology of autoimmune neuropathies and myopathies. Clin Neuropharmacol. 2002 May-Jun; 25(3):174-81. PMID: 12023571.
      View in: PubMed
    46. Rowin J, Meriggioli MN, Cochran EJ. Monomelic amyotrophy with late progression. Neuromuscul Disord. 2001 Apr; 11(3):305-8. PMID: 11297947.
      View in: PubMed
    47. Meriggioli MN, Barboi AC, Rowin J, Cochran EJ. HMG-CoA Reductase Inhibitor Myopathy: Clinical, Electrophysiological, and Pathologic Data in Five Patients. J Clin Neuromuscul Dis. 2001 Mar; 2(3):129-34. PMID: 19078619.
      View in: PubMed
    48. Meriggioli MN, Rowin J. Treatment of myasthenia gravis with mycophenolate mofetil: a case report. Muscle Nerve. 2000 Aug; 23(8):1287-9. PMID: 10918271.
      View in: PubMed
    49. Rowin J, Meriggioli MN. Electrodiagnostic significance of supramaximally stimulated A-waves. Muscle Nerve. 2000 Jul; 23(7):1117-20. PMID: 10883008.
      View in: PubMed
    50. Meriggioli MN, Rowin J. Chronic inflammatory demyelinating polyneuropathy after treatment with interferon-alpha. Muscle Nerve. 2000 Mar; 23(3):433-5. PMID: 10679722.
      View in: PubMed
    51. Meriggioli MN, Rowin J, Sanders DB. Distinguishing clinical and electrodiagnostic features of X-linked bulbospinal neuronopathy. Muscle Nerve. 1999 Dec; 22(12):1693-7. PMID: 10567082.
      View in: PubMed
    52. Rowin J, Meriggioli MN. Complex repetitive discharges: cause or effect of neurogenic muscle hypertrophy? Muscle Nerve. 1999 Nov; 22(11):1603-6. PMID: 10514243.
      View in: PubMed
    53. Rowin J, Meriggioli MN, Cochran EJ, Sanders DB. Prominent inflammatory changes on muscle biopsy in patients with Miyoshi myopathy. Neuromuscul Disord. 1999 Oct; 9(6-7):417-20. PMID: 10545047.
      View in: PubMed
    54. Meriggioli MN, Sanders DB. Conduction block and continuous motor unit activity in chronic acquired demyelinating polyneuropathy. Muscle Nerve. 1999 Apr; 22(4):532-7. PMID: 10204791.
      View in: PubMed
    55. Camici M, Giordani R, Morelli E, Meriggioli M, Balestri PL, Barsotti G, Sagripanti A. Safety and efficacy anticoagulation in extracorporeal hemodialysis by simultaneous administration of low-dose prostacyclin and low molecular weight heparin. Minerva Med. 1998 Nov-Dec; 89(11-12):405-9. PMID: 10212664.
      View in: PubMed
    56. Barsotti G, Cupisti A, Ferdeghini M, Meola M, Battini S, Cozza V, Meriggioli M, Barsotti M. Circulating levels of IGF-I in patients with chronic uremia on conservative dietary treatment. Ren Fail. 1998 Mar; 20(2):357-60. PMID: 9574463.
      View in: PubMed
    57. Meriggioli MN, Morgenlander JC. Peripheral neuropathy and connective tissue disease. Watch for this twosome when hunting for a diagnosis. Postgrad Med. 1997 Nov; 102(5):65-8, 71, 75. PMID: 9385332.
      View in: PubMed
    58. Camici M, Evangelisti L, Balestri P, Cioni L, Rindi P, Sagripanti A, Meriggioli M, Giordani R. Coagulation activation in extracorporeal hemodialysis. Int J Artif Organs. 1997 Mar; 20(3):163-5. PMID: 9151152.
      View in: PubMed
    59. Camici M, Evangelisti L, Balestri P, Cioni L, Rindi P, Sagripanti A, Meriggioli M, Giordani R. [Coagulation in hemodialysis]. Minerva Med. 1996 Nov; 87(11):509-14. PMID: 9045101.
      View in: PubMed
    Meriggioli's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    See all (277) concept(s)
    _
    Co-Authors Expand Description
    See all (5) people
    _
    Similar People Expand Description
    See all (60) people
    _
    Same Department Expand Description
    Search Department